Dow Jones Newswires: Roche extends tender offer for Spark Therapeutics

This post was originally published on this site

Roche Holding AG said the offer was extended to provide additional time for the U.S. Federal Trade Commission and the U.K. Competition and Markets Authority to complete their reviews of the pending acquisition.

The period for Roche’s ROG, +0.28% offer of $114.50 per share has been extended several times and was set to expire on Dec. 10.

As of Dec. 6, around 14.9% of Spark’s ONCE, +0.88%  outstanding shares had been tendered, according to Roche.